Minnesota Patent of the Month – November 2024

Rebiotix Inc., has pioneered a groundbreaking method for preparing fecal microbiota compositions, offering a transformative approach to combating recurrent Clostridium difficile (C. diff) infections. This innovative process leverages donor fecal samples, meticulously screened for pathogens and processed into homogenized and filtered microbiota compositions. By integrating a cryoprotectant such as glycerol, the compositions are safeguarded during freezing and storage, ensuring their efficacy and stability.

The process is centralized for precision and scalability, encompassing rigorous pathogen screening and careful labeling to index donor information. Packaged in various delivery formats, including enema bags, oral capsules, and containers for colonoscopic or nasogastric administration, these compositions cater to diverse clinical needs. Once prepared, the microbiota compositions can be stored as frozen units, ready to be dispatched upon request for timely administration to patients.

This innovation addresses a critical medical challenge. C. diff infections, often triggered by antibiotics that disrupt gut flora, can lead to severe gastrointestinal distress and life-threatening conditions. By restoring a healthy microbiome through fecal microbiota transplantation (FMT), this method reduces the risk of infection recurrence. The process ensures the highest standards of safety and reliability, setting a new benchmark in microbiota-based therapies.

Rebiotix’s approach not only refines FMT but also opens the door to broader applications of microbiome therapeutics. With its centralized processing and robust storage capabilities, this invention paves the way for scalable solutions that can benefit patients worldwide. As the demand for microbiome-centered treatments grows, Rebiotix’s innovation represents a vital step forward in harnessing the potential of the human microbiota to improve health outcomes.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Recent Posts